Market Research Reports and Industry Reports

TAKEDA , Challenges Ahead for its New European Presiden

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr. Weber will transform Takeda in a truly global Japanese company in the coming years. It is however important to see how he fulfills the Japanese expectation from these acquisitions and fills the gap for Takeda due to the recent failure of its key late stage pipeline candidates (TAK-875, TAK-700 in chemo experienced Prostate Cancer). From its remaining late stage pipeline candidates (Table 2) Vedolizumab, Contrave (Naltoxone + buproprion, obesity) and MLN-9708 (Ph III, Ixazomib, Multiple Myeloma) are important to drive its growth. Of the recent small to mid-sized consolidation activities in 2013 (Table 1), deals done with Natrogen (New-York, Natura alpha, IBD), Resolve therapeutics, and Inviragen demonstrate Takedas focused approach for selective therapy areas (GI Speciality, Autoimmune, Vaccines), while its deal with Arbor for out licensing EDARBI US rights reveals its decreasing focus on primary care therapy area for global market.Vortioxetine (Brintellix) US launch for MDD Likely in Early 2014 Competitive Enough Against Genericized MDD Market, Edivoxetine failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, 47 integrin inhibitor, Ulcerative colitis / Crohns disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late stage two key candidates: Vedolizumab approval in 2014 in UC/CD by mid 2014 is key to watch out for-MLN-9708/Velcade- Our View on Takedas Multiple Myeloma franchise-TAK-700 - Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo nave pool and in earlier setting?- This 30 page detailed report on Takeda pharmaceuticals provide insightful analysis on its recent M & A activities and potential of late stage pipeline candidates based on their global competitive landscape
Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

List Of Tables

Chart 1 Anti-Depressants WW Competitive Landscape
- chart 2 : MLN9708 -Trial design of TOURMALINE-MM1 RRMM
- chart 3 : REPORTED ADVERSE EVENTS IN CLINICAL TRIALS -MLN9708
-Chart 4: TAK-700 - DRUGS ACTING THROUGH ANDROGEN PATHWAY IN PC
-Chart 5: Nesina US Prescription trend

List Of Figures

Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

Takeda Pharmaceutical Company Ltd (4502) - Financial and Strategic SWOT Analysis Review

Takeda Pharmaceutical Company Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125View Report

Takeda – Singen Dengue Vaccine Manufacturing Plant – Baden-Württemberg Project Profile

Synopsis Takeda Singen Dengue Vaccine Manufacturing Plant Baden-Wrttemberg Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership

USD 75View Report

Takeda Pharmaceutical Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Takeda Pharmaceutical Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Takeda Pharmaceutical Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

5G for FWA (Fixed Wireless Access): 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts

The market is expected to grow at a CAGR of approximately 84% between 2019 and 2025, eventually accounting for more than $40 Billion.

USD 2500View Report

Big Data in the Healthcare & Pharmaceutical Industry: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Market research estimates that Big Data investments in the healthcare and pharmaceutical industry will account for nearly $4 Billion in 2017 alone.

USD 2500View Report

Personal Wipes: Trends, Challenges, Growth Potential

With significant untapped potential in the developing countries and room for growth in the developed regions, personal wipes often top the industry agenda. The report provides a global overview of

USD 1325View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 500
  • Site Licence    USD 1000
  • Enterprisewide Licence    USD 1500
$ 500

Reports Details

Published Date : Jan 2013
No. of Pages :24
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop